BPDA2

Cat. No.:	HY-152208
CAS No.:	2907659-86-1
Molecular Formula:	$C_{24}H_{30}O_5$
Molecular Weight:	398.49
Target:	SHP2
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC_{50}s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes[1].

In Vitro

BPDA2 (0.2-3.2 μM) inhibits basal activation of Akt and ERK1/2 in a concentration dependent manner[1].
BPDA2 (0.25-4.0 μM; for 10 days) suppresses the anchorage independent growth and cancer stem cell properties of breast cancer cells in a concentration dependent manner[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	JIMT-1, MDA-MB468 cell
Concentration:	0.2, 0.4, 0.8, 1.6, 3.2 μM
Incubation Time:	
Result:	Inhibited basal activation of Akt and ERK1/2 in a concentration dependent manner.

REFERENCES

[1]. Dhanaji M Lade, et al. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects. Eur J Med Chem. 2023 Feb 5;247:115017.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA